ARTICLE | Financial News

AdvanDx secures $12 million in B-1 round

April 9, 2014 12:22 AM UTC

Molecular diagnostics company AdvanDx Inc. (Woburn, Mass.) raised $9 million in a $12 million series B-1 round led by new investor Merck Global Health Innovation Fund. Existing investors SLS Ventures and LD Pensions also participated. AdvanDx declined to disclose the trigger for the remaining $3 million. Merck's David Rubin joined AdvanDx's board. ...